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BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
BACTEREMIA ON HOSPITALS IN THE UNITED STATES: RESULTS FROM A
NATIONAL DATABASE
Kamble S, Shah AJ, Gemmen E
Quintiles Outcome, Rockville, MD, USA
OBJECTIVES: Previous studies have documented the impact of bacteremia involv-
ing Methicillin-resistance (MRSA) in patients with Staphylococcus aureus bactere-
mia, but recent estimates using nationally representative data are not available.
This study compares in-hospital mortality, length of stay (LOS) and total costs
between hospital discharges for MRSA and methicillin-susceptible (MSSA) S. au-
reus bacteremia. METHODS: Using the 2008-2009 Nationwide Inpatient Sample
(NIS) data of the Healthcare Cost and Utilization Project, we developed two groups
(age18 years): MRSA bacteremia (ICD-9-CM codes: 041.12, V09.0 and 790.7) and
MSSA bacteremia (ICD-9-CM codes: 041.11 and 790.7). Given the skewed distribu-
tion of in-hospital costs and over-dispersion of LOS, generalized linear model (GLM)
with gamma and negative binomial variance functions were evaluated to compare
in-hospital costs and LOS, respectively, between groups. Logit model was used to
compare inpatient mortality between groups. Gender, age, payer, 11 comorbidities,
and hospital characteristics, including hospital location, teaching status, bed size,
ownership type, and hospital region served as covariates in all regression models.
RESULTS: Patients with MRSA (vs. MSSA) bacteremia were reported as a discharge
diagnosis for 0.06% (vs. 0.05%) or 44,157 (vs. 37,653) of all hospital inpatient stays
among adults. MRSA bacteremia inpatients had relatively longer length of hospital
stay (12.5 vs. 11.1 days;P0.01), higher total costs ($22,263 vs. $21,330;P0.02), and
increased risk of in-hospital death (2.97% vs. 2.71%;P0.29) than inpatients with
MSSA bacteremia. After adjustment for patient and hospital characteristics, MRSA
bacteremia incurred 10.5% (CI:7.2-14.0%;P0.01) longer stays, 5.6% (CI:2.0-9.4%;
P0.01) higher inpatient costs, and 0.3% (CI:17.5-22.0%;P0.97) higher inpatient
mortality than MSSA bacteremia. The annual adjusted mean incremental total
inpatient cost associated with MRSA was $1,159 (SE: $379;P0.01) per
patient-discharge. CONCLUSIONS:MRSA bacteremia represents a considerable at-
tributable burden relative to MSSA bacteremia in the US hospitals. Continued ef-
forts towards preventing MRSA infections would provide significant potential ben-
efits by reducing hospital resource use and costs.
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CLINICAL AND ECONOMIC BURDEN OF COMMUNITY ACQUIRED PNEUMONIA
IN 7 COUNTRIES. A COMPARISON WITH INVASIVE PNEUMOCOCCAL DISEASE
Delgleize E, Topachevskyi O
GlaxoSmithKline Vaccines, Wavre, Belgium
OBJECTIVES:To compare the clinical and economic burden of community acquired
pneumonia (CAP) with invasive pneumococcal diseases (IPD) in children less than
10 years of age, based on cost-effectiveness studies from 7 countries. METHODS:
The clinical and economic burden of IPD and CAP hospitalisations in children less
than 10 years of age over 1 year was modelled based on published cost-effective-
ness studies of pneumococcal vaccines in UK, Canada, Czech Republic, Sweden,
Turkey, Saudi Arabia and Taiwan. Only direct medical costs were taken into ac-
count. The costs were converted in 2005 PPP adjusted international dollars (I$).
RESULTS: Model projections indicate that hospitalised CAP is more prevalent than
hospitalised IPD in children. The IPD case fatality ratio was found to be higher than
for CAP in all 7 countries evaluated. The projected total number of deaths related to
CAP was, however, estimated to be higher than for those of IPD in all countries
except in Canada and Sweden. The total estimated direct medical costs of CAP
compared with IPD were found to be on average 8.2 times higher in Europe and
North America and 37.8 times higher in Middle East and Asia Pacific regions. The
total CAP economic burden per year in children in the included studies was esti-
mated at: 57Mio I$ in UK; 65Mio I$ in Canada; 8.6Mio I$ in Czech Republic; 10.7Mio
I$ in Sweden; 3Mio I$ in Turkey; 5.7Mio I$ in Saudi Arabia and 30.3Mio I$ in Taiwan.
CONCLUSIONS: Model projections indicate that the mortality burden of CAP was
found to be higher than for IPD in the majority of countries studied. The total
economic burden of CAP in children is on average 8.2-37.8 times higher than for IPD
across 7 countries.
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LENGT OF STAY AND COSTS FOR PATIENTS WITH RECURRENT CLOSTRIDIUM
DIFFICILE INFECTIONS IN SWEDEN
Norén T1, Bruce S2, Fagerlund K3, Nordling S3
1Department of Infectious Diseases, Örebro, Sweden, 2IMS Health, Stockholm, Sweden, 3Astellas
Pharma Nordic, Kastrup, Denmark
OBJECTIVES: To collect real world data on length of stay and attributable costs at
hospital wards for patients with CDI in a Swedish inpatient care setting.METHODS:
The CEBRxA database was used, which combines data from a health resource
utilization database for inhabitants in the greater Gothenburg area, with national
Swedish registers on prescription drug use and mortality. All CDI events (ICD-10
code A04.7) were collected during the years 2005 to 2009. CDI admissions were
defined as new or recurrent, i.e. new admission within 42 days from discharge. CDI
care contacts were explored in the strata of new-/recurrent CDI with CDI diagnose
in primary/other position. RESULTS: A total of 2,338 care contacts (1,689 patients)
of which 82% was inpatient, were identified. New CDI care contacts accounted for
1,883 and recurrent care contacts for 455. Recurrent care contacts were 1.36 times
more likely to have the CDI diagnosis in first position compared to new care con-
tacts (P3.078e-10), corresponding to 64% (290/455). The mean length of stay for
recurrent care contacts, with CDI in other diagnose positions, was 15.9 days com-
pared to CDI in primary position, 7.3 days. The mean cost for recurrent CDI in
primary position was 24,710SEK and 57,910SEK for CDI in other diagnose position.
When allowing the CDI diagnosis to be in any position, the mean length of stay was
10.5 days with a mean cost of 37,020SEK.CONCLUSIONS:The mean cost and length
of stay for patients with CDI varied considerably depending on whether the CDI
diagnosis was in primary position or included as a complicating factor to pre-
existing disease, i.e. other diagnose position. There would be a large potential for
cost savings if recurrent CDI could be avoided.
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COST IMPLICATIONS OF DIFFERENT PRACTICES IN VACCINE PROVISION
Maervoet J, Pasmans R, Saka Ö
Deloitte, Diegem, Belgium
OBJECTIVES: Given that vaccination systems vary widely between countries, we
investigated the cost implications of different ways of organising vaccine provision
in order to identify best practices.METHODS:We evaluated vaccination systems in
six EU countries by investigating the provision of several paediatric and adult vac-
cines. We validated our findings through interviews with academics, country ex-
perts and executives from large vaccine manufactures. We built a tool to simulate
the impact of alternative policies on all cost components relevant in vaccine
provision. RESULTS: Our findings suggest that vaccine procurement, distribution
and administration are the three key areas for potential efficiency gains for vaccine
provision. While procurement through tenders requires careful planning and prep-
aration, it does seem to be an effective, short-term method for health care payers to
obtain lower vaccine purchase prices. Policy makers may, however, need to con-
sider that anticipated savings can be partly offset by increased wastage due to
over-ordering and losses in social contributions. Examples from the six investi-
gated countries confirm these cost components can become relevant. The main
economical benefits may lie further downstream: i.e. in a more efficient provision
of vaccines through alternative distribution and vaccine administration channels.
Distribution can be organised directly to pharmacies or vaccinators by specialised
cold chain logistics providers (such as for childhood vaccine distribution in UK)
while the number and types of vaccinations settings can be extended to non-
traditional settings such as schools (Belgium), pharmacies (Ireland), and vaccina-
tion centres (Greece). Based on “what-if simulations”, common efficiency gains of
€10 to €15 per vaccination might be achieved in distribution and administration.
CONCLUSIONS: By applying best practices in the distinct areas of vaccine procure-
ment, distribution and administration, vaccine provision can be organised in a
more cost-effective way. Policy makers should take these into consideration when
choosing a specific practice for vaccine provision.
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EUROPEAN REFERENCE PRICING FOR VACCINES IN GERMANY: MECHANICS
AND EFFECTS
Hammerschmidt T1, Barth J2
1GlaxoSmithKline, Munich, Germany, 2-, Feucht, Germany
OBJECTIVES: In 2011, Germany introduced a European reference pricing (ERP) sys-
tem for vaccines in order to bring down the German vaccine prices to an assumed
smaller European level. Description of the mechanism of the ERP-system. Analysis
of effects on prices in the vaccine portfolio of GlaxoSmithKline (GSK). Further, we
evaluate the impact of ERP-system in the influenza vaccine market (8 vaccines, 5
manufacturers). METHODS: The description of the mechanism is based on the law
and corresponding regulations of the head association of sickness funds (GKV-SV).
We analyze the relation of the German and the European reference prices in the
GSK portfolio. In the influenza market, we analyze the price reduction and the
spread of prices before and after reference pricing. RESULTS: According to German
law, ERP is based on manufacturer-selling-prices in four European countries with a
gross domestic product (GDP) matching Germany best (i.e. UK, France, Italy, Spain)
weighted by purchasing-power-parities (PPP) and sales. GKV-SV extended this bas-
ket to the countries with closest GDP to Germany in which the vaccine is marketed.
Only 9 of 20 GSK-vaccines are marketed in the four countries considered by the law,
Poland and Belgium become relevant countries in the extended basket. For 10
vaccines, GlaxoSmithKline pays a mean rebate of 38% (min:2%,max:66%;95%-CI:
[25%;51%]). For the remaining 10 vaccines the ERP is 18%(min:1%,max:79%;95%-CI:
[3%;33%]) above the German price. In the flu vaccine market, ERP-system reduces
the pharmacy-selling-prices by 37%-69% (pack size 1) or 32%-63% (pack size 10) and
widens the price range from 10% to 118% (pack size 1) or 6% to 84% (pack size 10)
while changing the price order of the vaccines.CONCLUSIONS: European reference
prices are not generally lower than German prices. In the most competitive vaccine
market of influenza vaccines, the ERP-system lowers the prices, but seems to dis-
tort the market prices.
PIN90
TOWARDS BEST PRACTICES FOR HANDLING UNCERTAINTIES IN HEALTH
TECHNOLOGY ASSESSMENTS FOR HPV VACCINATION TO BETTER INFORM
DECISION MAKING
Siebert U1, Castellsague X2, Lee Mortensen G3, La Torre G4
1UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 2Institut Català
d’Oncologia (ICO), L’Hospitalet de Llobregat (Barcelona), Spain, 3AnthroConsult, Aarhus C,
Denmark, 4Sapienza University of Roma, Roma, Italy
OBJECTIVES: HTAs for human papillomavirus (HPV) vaccination have been con-
ducted by health authorities or HTA agencies in most western European countries
and played an important role in the decision-making for implementing HPV vac-
cination in girls. Our research aims to stress lessons learnt from past HTAs and to
suggest general best practices for future HTAs of HPV vaccination. METHODS: A
comprehensive research was conducted into the current HTA landscape in West-
A401V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
ern Europe. A multidisciplinary and pan European experts’ working group has been
established to discuss the development of best practices to optimise future HTAs
for HPV vaccination. RESULTS: Our research shows that a systematic, transparent
and comprehensive approach was inconsistently used in previous HTAs leading to
different conclusions. However, all HTAs raised some uncertainties and remaining
open questions at time of assessment that need to be further addressed. The ex-
perts’ group reached consensus on the following points: 1) Epidemiological trends
and projections of HPV infection and diseases should be considered to better esti-
mate the expected impact of vaccination on HPV burden; 2) Changes in knowledge,
perceptions and attitudes towards HPV vaccination should be documented, as they
may affect the medical and economical efficiency of vaccination programmes. 3)
Dynamic transmission models (accounting for herd immunity) should be used,
considering decision-analytic aspects (incremental comparisons, time horizon,
discounting, model validation), to help assessors handling validity and uncertain-
ties on key parameters (HPV transmission, vaccine effectiveness, duration of pro-
tection); 4) HPV vaccination as any health technology should be subject to an on-
going HTA process that integrates new monitoring outcomes and research
findings. CONCLUSIONS: HTAs of HPV vaccination were used to inform policy-
making for girls’ vaccination, while uncertainties remained at first assessment
time. Evidence generated since latest HTA should continuously be integrated in
new HTAs, to better inform country policy decisions and adjust/extend policies in
place accordingly.
RESEARCH POSTER PRESENTATIONS – SESSION III
SELECTED HEALTH CARE TREATMENT STUDIES
SURGERY - Clinical Outcomes Studies
PSU1
3-YEAR REAL-WORLD OUTCOMES WITH THE SWEDISH ADJUSTABLE GASTRIC
BANDTM IN FRANCE
Ribaric G
Johnson & Johnson, Norderstedt, Germany
OBJECTIVES: To prospectively ascertain outcomes typical of the French national
experience with the Swedish Adjustable Gastric BandTM (SAGBTM) in a consecu-
tive-series, patient sample. METHODS: A common protocol for prospective data
collection was provided to both urban and rural centres across regions of continen-
tal France. The protocol stipulated collection of data for body mass index (BMI,
kg/m2), excess weight (kg), comorbidities, quality of life (QoL), and adverse events.
RESULTS: Thirty-one surgeons in 28 teams implanted SAGBs.The cohort of 517
patients included 88.0% female; mean age of 37.5 years; mean disease duration,
15.3 years; mean preoperative BMI, 41.2. Measures of obesity were significantly
reduced at 3 years, with a within-patient mean BMI reduction of 9.0 (95% CI: 8.5, 9.5;
p0.0001), excess body weight reduction of 24.5 kg (23.1, 25.9; p0.0001), and cor-
responding 47.4% EWL (44.3, 51.0). Arthropathy, hypertension, dyslipidemia, and
gastro-oesophageal reflux disease were the 4 most frequently cited comorbidities.
Comorbidity prevalence fell significantly from a baseline of 74.3% (773 reported
comorbidities in 381/513) to 27.2% (161 comorbidities in 116/424); thus, at 3-year
follow-up, 72.8% reported no comorbidity. The majority of SAGB patients (68.3%)
experienced no adverse events. Confirmed adverse events associated with the
SAGB procedure totaled 290, occurring in 31.7% of patients. An overall adverse
event rate of 0.19 events per patient-year.There was 1 unrelated death.Obesity-
specific BAROSTM and non-disease specific Euro-QoLTMpresented improvement
in QoL over 3 years post-SAGB implantation. Global QoL improvement was signif-
icantly associated with magnitude of BMI reduction (p0.001) CONCLUSIONS:
SAGB was effective at 3 yrs; BMI was reduced by 9.0 kg/m2, from 41.0 to 32.2 kg/m2.
Average number of comorbidities per patient decreased over time. The 3-year im-
plant-survival rate was 87.0%. SAGB-induced weight loss was associated with sub-
stantially improved QoL.
PSU2
THE INCIDENCE OF COMPLICATIONS AFTER ITS THYROIDECTOMY IN
PATIENTS WITH THYROID CANCER IN KOREA : USING HEALTH CLAIM
DATABASE
Hyun MK1, Kim J1, Kwon JW1, Park YJ2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul
National University College of Medicine, Seoul, South Korea
OBJECTIVES: Thyroidectomy is the treatment of choice in most thyroid cacner
patients; however the incidence of complications after thyroidectomy cannot be
bypassed. However, there are few studies about the complication after thyroidec-
tomy using nationwide health claim data. The aim of this study was to investigate
the incidence of complications after thyroidectomy in patients with thyroid cancer
and its risk factor in South Korea. METHODS: We used national health claim data-
base between 2006 and 2010 including all hospital records covering almost every
population by national health insurance system. We included patients aged 20-120
years old with thyroid cancer ( ICD-10 codes of C73*) who underwent throidecto-
my(P4551-4, P4561) in 2008. To select newly diagnosed patients in 2008, we ex-
cluded all patients who were previously reported to have any type of cancer in-
cluding thyroid cancer, hypoparathyroidism, or vocal cord paralysis between 2006
and 2007. We conducted a follow-up survey of the selected subjects on the national
health claim database at least for 2 years after diagnosis. RESULTS: Patients who
underwent thyroidectomy for thyroid cancer treatment 15,811 (mean age:
48.112.6 years). Complication after surgery occurred in 1,148 (7.3%) patients dur-
ing follow up of 2.4 years; 5.7% of hypoparathyroidism and 1.7% vocal cord paral-
ysis. Only 3.6% of complication (2.6% hypoparathyroidism and 0.6% vocal cord
paralysis) was reported within 1 month after surgery. The development of compli-
cation was significantly related with higher age, highly advanced general hospital,
urban region. CONCLUSIONS: This study results suggest that postoperative care
for patients with thyroidectomy is important to detect complications and to treat
them appropriately especially in elderly. Further more study is required to identify
risk factors of complication after thyroidectomy.
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PROLONGED EFFECTIVENESS OF CORONARY ARTERY BYPASS SURGERY
VERSUS DRUG-ELUTING STENTS IN DIABETICS WITH MULTI-VESSEL DISEASE:
AN UPDATED META-ANALYSIS
Ariyaratne TV1, Ademi Z2, Yap CH3, Billah B1, Rosenfeldt F4, Yan BP5, Reid CM1
1Monash University, Melbourne, Victoria, Australia, 2University of Melbourne, Melbourne,
Australia, 3Geelong Hospital & Monash University, Geelong, Victoria, Australia, 4Alfred Hospital
& Monash University, Melbourne, Victoria, Australia, 5Prince of Wales Hospital & Monash
University, Hong Kong, Hong Kong, China
OBJECTIVES: Individuals with pre-existing multi-vessel disease (MVD) and type-II
diabetes mellitus (DM) are at increased risk of complications following coronary
revascularisation. The global rise in prevalence of DM warrants frequent monitor-
ing of medium-term outcomes in real-world patients undergoing contemporary
coronary artery bypass surgery (CABG) or percutaneous coronary intervention.
METHODS: We conducted a meta-analysis comparing the effectiveness of CABG
versus drug-eluting stents (DES) in the MVD-DM population. Using a set of pre-
specified criteria, a search strategy was developed to retrieve published reports to
date (April 2012) in the English language. An electronic search for non-randomised
controlled studies was conducted in five medical databases (MEDLINE, EMBASE,
PUBMED, CINAHL and the Cochrane). A panel comprising three reviewers were
involved in systematically screening the selected abstracts, whilst two performed
the data extraction. Data were pooled using both fixed- and random-effects mod-
els. Effects sizes were measured through relative risks (RR) and 95% confidence
intervals (CI). RESULTS: Of 13 reports that met our pre-specified criteria, we in-
cluded 11 studies which enrolled 4,162 patients (2,033 CABG and 2,129 DES). The
average length follow-up was 2.5 years (range 12- and 60-months). Whilst no sig-
nificant mortality benefit was observed by either CABG or DES at mean follow-up
(RR  0.9; 95%-CI: 0.6 to 1.3), CABG was associated with lower risk of myocardial
infarction (RR 0.5; 95%-CI: 0.4 to 0.8), repeat revascularisation (RR0.3; 95%-CI: 0.2
to 0.4), and MACCE (RR 0.7; 95%-CI: 0.6 to 0.8). In contrast, CABG was associated
with higher risk of cerebrovascular events (CVE) (RR 1.8; 95%-CI: 1.04 to 3.2). Both
procedures showed no significant difference in the combined outcome of all-cause
mortality, myocardial infarction or CVE (RR  0.9; 95%-CI: 0.8 to 1.1).
CONCLUSIONS: In a real-world population we demonstrated a unique finding of
increased risk of myocardial infarction with DES compared to CABG at mean fol-
low-up of 2.5 years.
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REGIONAL VARIATION IN ANGIOGRAM USE FOR PATIENTS WHO UNDERWENT
CORONARY ARTERY BYPASS GRAFT SURGERY
Baser O1, Burkan A2, Baser E3, Koselerli R2, Ertugay E2, Altinbas A4
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2Social Security
Institution, Ankara, Turkey, 3STATinMED Research, Istanbul, MI, Turkey, 4Dýskapý Yýldýrým
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OBJECTIVES: Angiograms, whereby a tube is inserted in the arm or groin area and
threaded up to the heart to check for blocked arteries that may cause a heart attack,
is a necessary but complicated and expensive procedure. This study analyzed the
potential overuse of angiograms among patients who underwent coronary artery
bypass graft (CABG) surgery in Turkey. METHODS: Using the Turkish National
Health Insurance Database, patients undergoing CABG surgery in 2010 were iden-
tified using the appropriate International Classification of Disease 10th Revision
Clinical Modification (ICD-10-CM) diagnosis codes. From this group, patients with
more than one angiogram 3 months before surgery were identified. Regional vari-
ations were identified using a color-coded map. The relationship between hospital
quality and angiogram intensity was assessed using chi-square tests. Hospital
quality was determined using the previously validated CompQual index, which
uses hospital operational mortality and volume as inputs. RESULTS: Out of 39,410
patients identified, 6.65% had more than one angiogram 3 months prior to CABG
surgery. There was a wide variation in angiogram use across cities. The proportion
of CABG surgery patients with more than one angiogram was the highest in
Tekirdag (14.46%), followed by Afyonkarahisar (12.23%) and Erzurum (10.66%).
There was a significant relationship between hospital quality and overuse of an-
giograms. The highest quality hospitals had a higher proportion of patients with a
single angiogram prior to CABG surgery (p0.001). CONCLUSIONS: Angiograms,
although significantly important to detect blocked arteries, should be applied ef-
fectively. Excessive use of angiograms not only decreases the quality of health care
but also increases health care costs.
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BARIATRIC SURGERY FROM THE PERSPECTIVE OF BRAZILIAN NATIONAL
HEALTH SYSTEM (SUS)
Freitas MG1, Souza KM2, Silva MT3, Elias FTS4
1Brazilian Ministry of Health, Brasilia, Distrito Federal, Brazil, 2Brazilian Ministry of Health, Belo
Horizonte, Minas Gerais, Brazil, 3Brazilian Ministry of Health, Brasília, DF, Brazil, 4Ministry of
Health of Brazil, Brasilia, Distrito Federal, Brazil
OBJECTIVES: Bariatric surgery is highly complex process indicated for treating
morbid obesity. In the SUS the surgery provided is the laparotomical way. Objec-
tives of the study were: Elaboration of a rapid review about the effectiveness and
economical analysis of the bariatric surgery methods for the decision of incorpo-
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